dm+d

Unassigned

New Medicines

Acute graft versus host disease (GvHD)

Information

New molecular entity
Merck Sharp & Dohme (MSD)
Merck & Co (name used in US for MSD)

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Jul 21MK-7110 no longer listed in MSD pipeline and recruitment halted in PIII CATHY trial; presume development has been discontinued [6].

Category

A recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
The number of allogeneic bone marrow and stem cell transplants is increasing worldwide. GvHD is a serious complication of this type of transplant. The incidence of acute GvHD varies widely, ranging from 10-80% depending on risk factors. Acute GvHD relates to the degree of HLA mismatch; thus, it is usual to try to match donors and recipients for these proteins, especially HLA-A, -B, -C and DRB1 [1].
Acute graft versus host disease (GvHD)
Intravenous infusion